RxDoctor Payments Data

John Bullock, MD

Ophthalmology · Orange Park, FLNPI 1750774634

Payments from drug & device makers

$1,498in general payments, 2019–2025

Across 46 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$572
  • Tarsus Pharmaceuticals, Inc.$240
  • Bausch & Lomb Americas Inc.$235
  • Johnson & Johnson Surgical Vision, Inc.$85
  • AbbVie$74
  • Alcon$69
  • plus $224 from 7 others

What the payments were for

  • Food & beverage$1,498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,498 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$435,137
Medicare patients
1,132
Services billed
3,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner44$82,452
RestasisCyclosporine78$70,522
MieboPerfluorohexyloctane/Pf16$12,349
Difluprednate43$4,876
Doxycycline Hyclate84$2,438
Latanoprost110$2,221
ErythromycinErythromycin Base192$1,949
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha172$1,830
Prednisolone Acetate65$1,795
Ofloxacin94$964
Timolol Maleate32$527
Brimonidine Tartrate14$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$240$82,45244 claims
AbbVieRestasis$74$70,52278 claims
Bausch & Lomb Americas Inc.Miebo$235$12,34916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →